Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of Tegoprazan 12.5 mg in Healthy Subjects
NCT06332638Phase 1Enrolling by invitation
- Sponsor
- HK inno.N Corporation
- Start
- Mar 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of tegoprazan in gastroesophageal reflux disease (GERD) (3 arms), sponsored by HK inno.N Corporation. Primary endpoints: Maximum Plasma Concentration at Day 1, Area Under the Curve from time 0 to last measurable concentration at Day 1 and 5 more. Started Mar 2024; status: enrolling by invitation.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06332638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06332638.